ANTICANCER DRUG DISCOVERY THAT TARGETS TUMOR HYPOXIA

针对肿瘤缺氧的抗癌药物的发现

基本信息

  • 批准号:
    7228963
  • 负责人:
  • 金额:
    $ 25.71万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2004
  • 资助国家:
    美国
  • 起止时间:
    2004-05-01 至 2008-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The objective of the proposed research is to identify and characterize small molecule natural product-derived regulators of tumor hypoxia. Solid tumors contain regions under low oxygen tension (hypoxia) and this lack of oxygen contributes to resistance to radiation treatment and chemotherapy. Hypoxia-associated treatment resistance can be caused directly through reduced cellular oxygen concentrations or indirectly through hypoxia-induced modifications in gene expression. Current efforts to overcome hypoxia target the direct effects of hypoxia. We propose a new approach that specifically targets this important indirect effect of hypoxia (alteration of tumor gene expression). The unique focus of this program is to identify and evaluate natural product-derived small molecules that target hypoxia-induced gene expression. A three-pronged approach that combines natural products chemistry with molecular biology will be employed to identify and investigate such small molecules. The first objective will involve isolating and determining the chemical structures of natural product-derived regulators of tumor hypoxia. Such regulators will target a number of processes that are unique to hypoxic tumor cells and key for tumor cell adaptation to hypoxia. A panel of high-throughput bioassays has been established to identify such regulators. Active compounds will be isolated through bioassay-guided fractionation and isolation, and their chemical structures elucidated using a combination of spectroscopic and spectrometric methods. Our group has established the proof of principle for this approach through preliminary research that has identified several potent new hypoxia inducible factor-1 (HIF-1) inhibitors. HIF-1 is a key transcription factor that activates the expression of survival genes under hypoxia. The second objective will identify target genes affected by newly identified active leads. Preliminary studies have revealed that natural product derived small molecules can either selectively inhibit hypoxic activation of HIF-1 or inhibit both hypoxic and chemical activation of HIF-1, depending upon the specific chemical class of each of inhibitor. Inhibition of HIF-1 activation is associated with reduction of the hypoxic induction of HIF-1 target gene vascular endothelial growth factor (VEGF), a potent initiator of tumor angiogenesis. Target genes will be identified by microarray analysis. The third objective will focus on biochemical and cell biological investigations of the mechanisms by which newly identified active natural products regulate hypoxic signaling. Accomplishing these objectives will provide drug leads and molecular probes that target tumor hypoxia and afford new insights into the intracellular pathways affected by these molecules.
描述(由申请人提供):拟议研究的目的是鉴定和表征肿瘤缺氧的小分子天然产物衍生调节剂。实体肿瘤包含低氧张力(缺氧)的区域,这种缺氧有助于对放疗和化疗的抵抗。低氧相关的治疗抗性可以通过细胞氧浓度降低直接引起,也可以通过低氧诱导的基因表达修饰间接引起。目前克服缺氧的努力主要针对缺氧的直接影响。我们提出了一种新的方法,专门针对这种重要的间接影响缺氧(肿瘤基因表达的改变)。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DALE G NAGLE其他文献

DALE G NAGLE的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DALE G NAGLE', 18)}}的其他基金

ANTICANCER DRUG DISCOVERY THAT TARGETS TUMOR HYPOXIA
针对肿瘤缺氧的抗癌药物的发现
  • 批准号:
    6889494
  • 财政年份:
    2004
  • 资助金额:
    $ 25.71万
  • 项目类别:
ANTICANCER DRUG DISCOVERY THAT TARGETS TUMOR HYPOXIA
针对肿瘤缺氧的抗癌药物的发现
  • 批准号:
    7736794
  • 财政年份:
    2004
  • 资助金额:
    $ 25.71万
  • 项目类别:
ANTICANCER DRUG DISCOVERY THAT TARGETS TUMOR HYPOXIA
针对肿瘤缺氧的抗癌药物的发现
  • 批准号:
    8467682
  • 财政年份:
    2004
  • 资助金额:
    $ 25.71万
  • 项目类别:
ANTICANCER DRUG DISCOVERY THAT TARGETS TUMOR HYPOXIA
针对肿瘤缺氧的抗癌药物的发现
  • 批准号:
    7846221
  • 财政年份:
    2004
  • 资助金额:
    $ 25.71万
  • 项目类别:
ANTICANCER DRUG DISCOVERY THAT TARGETS TUMOR HYPOXIA
针对肿瘤缺氧的抗癌药物的发现
  • 批准号:
    7056196
  • 财政年份:
    2004
  • 资助金额:
    $ 25.71万
  • 项目类别:
ANTICANCER DRUG DISCOVERY THAT TARGETS TUMOR HYPOXIA
针对肿瘤缺氧的抗癌药物的发现
  • 批准号:
    7622893
  • 财政年份:
    2004
  • 资助金额:
    $ 25.71万
  • 项目类别:
ANTICANCER DRUG DISCOVERY THAT TARGETS TUMOR HYPOXIA
针对肿瘤缺氧的抗癌药物的发现
  • 批准号:
    8255354
  • 财政年份:
    2004
  • 资助金额:
    $ 25.71万
  • 项目类别:
ANTICANCER DRUG DISCOVERY THAT TARGETS TUMOR HYPOXIA
针对肿瘤缺氧的抗癌药物的发现
  • 批准号:
    6780202
  • 财政年份:
    2004
  • 资助金额:
    $ 25.71万
  • 项目类别:
ANTICANCER DRUG DISCOVERY THAT TARGETS TUMOR HYPOXIA
针对肿瘤缺氧的抗癌药物的发现
  • 批准号:
    8071564
  • 财政年份:
    2004
  • 资助金额:
    $ 25.71万
  • 项目类别:

相似海外基金

Delays in Acquisition of Oral Antineoplastic Agents
口服抗肿瘤药物的获取延迟
  • 批准号:
    9975367
  • 财政年份:
    2020
  • 资助金额:
    $ 25.71万
  • 项目类别:
Eliminate the difficulty of venous puncture in patients receiving antineoplastic agents - Development of a new strategy for the prevention of induration-
消除接受抗肿瘤药物的患者静脉穿刺的困难 - 制定预防硬结的新策略 -
  • 批准号:
    16K11932
  • 财政年份:
    2016
  • 资助金额:
    $ 25.71万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Molecular mechanisms of the antineoplastic agents inhibiting DNA replication and their applications to cancer patient treatmen
抗肿瘤药物抑制DNA复制的分子机制及其在癌症患者治疗中的应用
  • 批准号:
    19591274
  • 财政年份:
    2007
  • 资助金额:
    $ 25.71万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
PNET EXPERIMENTAL THERAPEUTICS--ANTINEOPLASTIC AGENTS AND TREATMENT DELIVERY
PNET 实验治疗——抗肿瘤药物和治疗实施
  • 批准号:
    6346309
  • 财政年份:
    2000
  • 资助金额:
    $ 25.71万
  • 项目类别:
TRAINING IN PHARMACOLOGY OF ANTINEOPLASTIC AGENTS
抗肿瘤药物药理学培训
  • 批准号:
    2720213
  • 财政年份:
    1999
  • 资助金额:
    $ 25.71万
  • 项目类别:
TRAINING IN PHARMACOLOGY OF ANTINEOPLASTIC AGENTS
抗肿瘤药物药理学培训
  • 批准号:
    6513197
  • 财政年份:
    1999
  • 资助金额:
    $ 25.71万
  • 项目类别:
Training in Pharmacology of Antineoplastic Agents
抗肿瘤药物药理学培训
  • 批准号:
    7101017
  • 财政年份:
    1999
  • 资助金额:
    $ 25.71万
  • 项目类别:
Training in Pharmacology of Antineoplastic Agents
抗肿瘤药物药理学培训
  • 批准号:
    6894842
  • 财政年份:
    1999
  • 资助金额:
    $ 25.71万
  • 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
  • 批准号:
    2885074
  • 财政年份:
    1999
  • 资助金额:
    $ 25.71万
  • 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
  • 批准号:
    6174221
  • 财政年份:
    1999
  • 资助金额:
    $ 25.71万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了